Genetic control of the circulating concentration of transforming growth factor type beta1.

The concentration of transforming growth factor beta (TGF-beta) in plasma has been correlated with the development of several diseases, including atherosclerosis and certain forms of cancer. However, the mechanisms that control the concentration of TGF-beta in plasma are poorly understood. In a study of 170 pairs of female twins (average age 57.7 years) we show that the concentration of active plus acid-activatable latent TGF-beta1 [(a+l) TGF-beta therefore is predominantly under genetic control (heritability estimate 0.54). Single strand conformation polymorphism (SSCP) mapping of the TGF-beta1 gene promoter has identified two single base substitution polymorphisms. The two polymorphisms (G-->A at position -800 bp and C-->T at position -509 bp) are in linkage disequilibrium (correlation coefficient Delta = 0.215, P < 0.01). The C-509T polymorphism is significantly associated with the plasma concentration of (a+l) TGF-beta1, explaining 8.2% of the additive genetic variance of (a+l) TGF-beta1 concentration. It is therefore possible that predisposition to atherosclerosis, bone diseases or various forms of cancer may be correlated with the presence of particular alleles at the TGFB1 locus.

[1]  D. Grainger,et al.  Transforming growth factor-beta dynamically regulates vascular smooth muscle differentiation in vivo. , 1998, Journal of cell science.

[2]  D. Grainger,et al.  Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. , 1997, Circulation.

[3]  E. Rubin,et al.  Feedback Mechanism of Focal Vascular Lesion Formation in Transgenic Apolipoprotein(a) Mice* , 1996, The Journal of Biological Chemistry.

[4]  D. Arveiler,et al.  Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Témoin de l'Infarctus du Myocarde (ECTIM) Study. , 1996, Hypertension.

[5]  D. Grainger,et al.  Tamoxifen: Teaching an old drug new tricks? , 1996, Nature Medicine.

[6]  D. Danielpour.  Induction of transforming growth factor‐β autocrine activity by all‐trans‐retinoic acid and 1α,25‐dihydroxyvitamin D3 in NRP‐152 rat prostatic epithelial cells , 1996 .

[7]  D. Grainger,et al.  Tamoxifen elevates transforming growth factor–β and suppresses diet–induced formation of lipid lesions in mouse aorta , 1995, Nature Medicine.

[8]  L. Wakefield,et al.  Release and activation of platelet latent TGF–β in blood clots during dissolution with plasmin , 1995, Nature Medicine.

[9]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[10]  A. Melman,et al.  Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer , 1995, Nature Medicine.

[11]  P. Weissberg,et al.  Active and acid-activatable TGF-β in human sera, platelets and plasma , 1995 .

[12]  A. Balmain,et al.  Lack of transforming growth factor-beta 1 expression in benign skin tumors of p53null mice is prognostic for a high risk of malignant conversion. , 1994, Cancer research.

[13]  R. Lawn,et al.  Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice , 1994, Nature.

[14]  Mahlon D. Johnson,et al.  Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. , 1993, The Journal of clinical investigation.

[15]  M. Anscher,et al.  Transforming Growth Factor β as a Predictor of Liver and Lung Fibrosis after Autologous Bone Marrow Transplantation for Advanced Breast Cancer , 1993 .

[16]  H. Stunnenberg.  Mechanisms of transactivation by retinoic acid receptors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[17]  Michael C. Neale,et al.  Methodology for Genetic Studies of Twins and Families , 1992 .

[18]  Michael R. Green,et al.  Retinoblastoma gene product activates expression of the human TGF-β2 gene through transcription factor ATF-2 , 1992, Nature.

[19]  M. Sporn,et al.  Evidence for Differential Regulation of TGFβ1 and TGFβ2 Expression in Vivo by Sandwich Enzyme‐linked Immunosorbent Assays , 1990 .

[20]  H. Koeppen,et al.  A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Sporn,et al.  Characterization of the promoter region of the human transforming growth factor-beta 1 gene. , 1989, The Journal of biological chemistry.

[22]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[23]  K. Lange,et al.  Extensions to pedigree analysis III. Variance components by the scoring method , 1976, Annals of human genetics.

[24]  A. Grace,et al.  The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis , 1995, Nature Medicine.

[25]  D. W. Johnson,et al.  Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 , 1994, Nature Genetics.

[26]  G. Torre-Amione.  A highly immunogenic tumor transfected with murine TGF-β1 cDNA escapes immune surveillance. , 1990 .

[27]  Robert C. Elston,et al.  Extensions to Pedigree Analysis , 1975 .